209 results on '"Barraco, Daniela"'
Search Results
2. Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry
3. Correction: Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry
4. Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation
5. Platelet count predicts driver mutations’ co-occurrence in low JAK2 mutated essential thrombocythemia and myelofibrosis
6. Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients
7. S173: RETROSPECTIVE STUDY OF LENALIDOMIDE DISCONTINUATION IN PATIENTS WITH MYELODYSPLASTIC SYNDROME HARBORING DEL(5Q). A HARMONY ALLIANCE STUDY
8. Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis
9. Targeted deep sequencing in polycythemia vera and essential thrombocythemia
10. Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anemia Due to Very Low, Low and Intermediate Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts, Who Had an Unsatisfactory Response to or Are Ineligible for Erythropoietin-Based Therapy: A Retrospective Multicenter Study By Fondazione Italiana Sindromi Mielodisplastiche (FiSiM ETS)
11. Chronic Myeloid Leukemia Diagnosed during Pregnancy: How to Manage? Description of 86 Cases from ELN International Registry
12. Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project
13. Momelotinib therapy for myelofibrosis: a 7-year follow-up
14. Gender and survival in essential thrombocythemia: A two‐center study of 1,494 patients
15. DNMT3A mutations are associated with inferior overall and leukemia‐free survival in chronic myelomonocytic leukemia
16. Real-World Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anaemia Due to Lower-Risk Myelodysplastic Syndromes with Ring Sideroblasts (MDS-RS), Who Had an Unsatisfactory Response to or are Ineligible for Erythropoiesis Stimulating Agents: A Retrospective, Multicenter, Cohort Study
17. Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia
18. Next generation sequencing of myeloid neoplasms with eosinophilia harboring the FIP1L1-PDGFRA mutation
19. Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation
20. Complete and long-lasting cytologic and molecular remission of FIP1L1-PDGFRA-positive acute eosinophil myeloid leukaemia, treated with low-dose imatinib monotherapy
21. Platelet count predicts driver mutations’ co-occurrence in low JAK2 mutated essential thrombocythemia and myelofibrosis
22. Long-term efficacy and safety of nilotinib therapy after imatinib failure in eosinophilic myeloproliferative neoplasm and ETV6-ABL rearrangement
23. Clinical factors predictive of myelofibrotic evolution in patients with polycythemia vera
24. Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia
25. Impact of Bone Marrow Fibrosis Grade in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis. a Study of the Mysec Group
26. Standard care and investigational drugs in the treatment of myelofibrosis
27. Platelet Count Predicts Co-occurrence of Driver Mutations in Essential Thrombocythemia and Myelofibrosis with a Low JAK2 Allele Burden
28. Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients
29. Hypopyon as the first sign of relapse in acute lymphoblastic leukaemia
30. Solid Tumors in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: A Study on 2220 Patients
31. Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project
32. Platelet count predicts driver mutations’ co-occurrence in low JAK2mutated essential thrombocythemia and myelofibrosis
33. Monocytosis is a powerful and independent predictor of inferior survival in primary myelofibrosis
34. Prefibroticversusovertly fibrotic primary myelofibrosis: clinical, cytogenetic, molecular and prognostic comparisons
35. Cytogenetic findings in WHO-defined polycythaemia vera and their prognostic relevance
36. Monocytosis in polycythemia vera: Clinical and molecular correlates
37. Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia
38. The prognostic relevance of serum lactate dehydrogenase and mild bone marrow reticulin fibrosis in essential thrombocythemia
39. DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia
40. Gene Expression Profiling Identifies Distinct Signatures for Dysplastic and Proliferative Chronic Myelomonocytic Leukemia
41. Risk Factors for Arterial Versus Venous Thrombosis in Polycythemia Vera: Single Center Experience in 587 Patients
42. Spectrum of Concomitant and Subsequently Diagnosed Second Malignancies in Patients with Chronic Myelomonocytic Leukemia
43. Prognostic Impact of Bone Marrow Fibrosis in Polycythemia Vera: Validation of the IWG-MRT Study and Additional Observations
44. U2AF1 Mutation Variants and Their Phenotypic and Prognostic Relevance in Primary Myelofibrosis
45. Identification of Serum Lactate Dehydrogenase (LDH) As an Independent Prognostic Biomarker in Polycythemia Vera
46. Abnormal Karyotype and Prognosis in Polycythemia Vera: A Single Center Experience in 239 Informative Cases
47. The Prognostic Relevance of Serum Lactate Dehydrogenase and Mild Reticulin Fibrosis in Essential Thrombocythemia
48. Monocytosis Is a Powerful and Independent Predictor of Shortened Overall and Leukemia-Free Survival in Primary Myelofibrosis
49. Prefibrotic Versus Overtly Fibrotic Primary Myelofibrosis: Clinical, Cytogenetic, Molecular and Prognostic Comparisons
50. Marked Elevation of Serum Lactate Dehydrogenase (LDH) in Primary Myelofibrosis: Clinical and Prognostic Correlates
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.